Arterial Thrombosis - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Arterial Thrombosis - Pipeline Review, H1 2019’, provides an overview of the Arterial Thrombosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Arterial Thrombosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Arterial Thrombosis

- The report reviews pipeline therapeutics for Arterial Thrombosis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Arterial Thrombosis therapeutics and enlists all their major and minor projects

- The report assesses Arterial Thrombosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Arterial Thrombosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Arterial Thrombosis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Arterial Thrombosis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Astellas Pharma Inc

Bristol-Myers Squibb Co

GLSynthesis Inc

Jiangsu Hengrui Medicine Co Ltd

Thromboserin Ltd

XBiotech Inc

Astellas Pharma Inc

Bristol-Myers Squibb Co

GLSynthesis Inc

Jiangsu Hengrui Medicine Co Ltd

Thromboserin Ltd

XBiotech Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Arterial Thrombosis – Overview

Arterial Thrombosis – Therapeutics Development

Pipeline Overview

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Arterial Thrombosis – Overview

Arterial Thrombosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Arterial Thrombosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Arterial Thrombosis – Companies Involved in Therapeutics Development

Astellas Pharma Inc

Bristol-Myers Squibb Co

GLSynthesis Inc

Jiangsu Hengrui Medicine Co Ltd

Thromboserin Ltd

XBiotech Inc

Arterial Thrombosis – Drug Profiles

ASP-6537 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bermekimab – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-654457 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GLS-409 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OA-150 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PZ-128 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-007867 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-2285 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PAI1 for Immunology, Respiratory and Cardiovascular Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Factor XIa for Arterial Thrombosis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THL-001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Arterial Thrombosis – Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Arterial Thrombosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Tables

Number of Products under Development for Arterial Thrombosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Arterial Thrombosis – Pipeline by Astellas Pharma Inc, H1 2019

Arterial Thrombosis – Pipeline by Bristol-Myers Squibb Co, H1 2019

Arterial Thrombosis – Pipeline by GLSynthesis Inc, H1 2019

Arterial Thrombosis – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2019

Arterial Thrombosis – Pipeline by Thromboserin Ltd, H1 2019

Arterial Thrombosis – Pipeline by XBiotech Inc, H1 2019

Arterial Thrombosis – Dormant Projects, H1 2019

Arterial Thrombosis – Dormant Projects, H1 2019 (Contd..1), H1 2019

List of Figures

List of Figures

Number of Products under Development for Arterial Thrombosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Figures

Number of Products under Development for Arterial Thrombosis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports